February 11, 2009
Article
One of three finalist essays for the 2008 CURE Extraordinary Healer Award Contest.
FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer
Lunsumio plus Polivy Associated With Responses in MCL
Standing Up to Cancer with Lynch Syndrome
Zidesamtinib Elicits Responses in ROS1-Positive NSCLC